J&J's crown jewel Stelara faces another potential rival as biosim player Alvotech touts trial win

Alvotech and its marketing partner Teva are coming for Johnson & Johnson’s $9 billion Stelara crown. On Tuesday, Alvotech revealed positive results from a clinical study for AVT04, its proposed Stelara biosimilar.